Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iradimed (IRMD) Capital Expenditures (2016 - 2025)

Historic Capital Expenditures for Iradimed (IRMD) over the last 13 years, with Q3 2025 value amounting to $1.1 million.

  • Iradimed's Capital Expenditures fell 7014.16% to $1.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.3 million, marking a year-over-year increase of 7855.27%. This contributed to the annual value of $8.0 million for FY2024, which is 758.72% up from last year.
  • As of Q3 2025, Iradimed's Capital Expenditures stood at $1.1 million, which was down 7014.16% from $2.6 million recorded in Q2 2025.
  • Iradimed's Capital Expenditures' 5-year high stood at $6.4 million during Q1 2023, with a 5-year trough of $91022.0 in Q4 2021.
  • Over the past 5 years, Iradimed's median Capital Expenditures value was $308086.0 (recorded in 2023), while the average stood at $1.3 million.
  • In the last 5 years, Iradimed's Capital Expenditures skyrocketed by 255015.21% in 2023 and then plummeted by 9576.97% in 2024.
  • Over the past 5 years, Iradimed's Capital Expenditures (Quarter) stood at $91022.0 in 2021, then surged by 134.6% to $213540.0 in 2022, then skyrocketed by 149.09% to $531903.0 in 2023, then surged by 424.56% to $2.8 million in 2024, then tumbled by 59.23% to $1.1 million in 2025.
  • Its last three reported values are $1.1 million in Q3 2025, $2.6 million for Q2 2025, and $3.7 million during Q1 2025.